Paradromics, a neurotechnology company, has successfully implanted its Connexus Brain-Computer Interface (BCI) in a human for the first time. The procedure, which took place on May 14, 2025, at the University of Michigan during an epilepsy surgery, involved the safe implantation and removal of the device within 20 minutes. The Connexus BCI successfully recorded neural signals during this period.
The Connexus BCI is designed to assist individuals with severe motor disabilities by translating brain signals into digital commands, such as typing on a computer. The device captures brain activity at the level of individual neurons and uses AI to translate these signals into actionable outputs. This milestone marks Paradromics' transition into clinical-stage neurotechnology.
Paradromics plans to initiate a more extensive clinical trial later in 2025, pending FDA approval, to evaluate the long-term safety and effectiveness of the Connexus BCI. The initial focus is to restore independent communication through digital devices for individuals living with spinal cord injuries, stroke, or ALS.